Knight Therapeutics to acquire Paladin Pharma from Endo for $135m.

Knight Therapeutics, a pan-American specialty pharmaceutical company, agreed to acquire Paladin Pharma, a Canada-based specialty pharmaceutical company, from Endo, a diversified pharmaceutical company, for $135m. "This synergistic transaction adds critical mass and significantly increases the size of our Canadian business. In addition, the acquisition adds a portfolio of stable cash flow generating pharmaceuticals that will help fund our growth in Canada and Latin America," Samira Sakhia, Knight Therapeutics President and CEO.